The BioHub: The Top Voices in Biotech

We were delighted to welcome Robert Ross, Chief Executive Officer at Clasp Therapeutics, onto The BioHub. Clasp Therapeutics are a pioneering biotech company spearheading the next generation of T-cell engager therapies. Founded in 2024 and backed by a successful $150 million Series A round with top tier investors, Clasp stands out for its novel approach in delivering off-the-shelf, bispecific T‐cell engagers that narrowly target cancer-driving mutations while sparing healthy tissues. Dr. Ross brings a wealth of experience to Clasp’s mission. Before stepping into the CEO role at Clasp in November 2023, he led Surface Oncology through its acquisition by Coherus Biosciences and directed oncology strategy at bluebird bio, where he played a key role in advancing groundbreaking CAR T-cell therapies.In this episode we dive into inspiration behind the founding of Clasp, what it takes to build a biotech and the shift from preclinical to clinical, an insight into some of the work Clasp are doing, as well as Rob transitioning from a practicing Oncologist to a Biotech CEO.

Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry.I’m joined by Aaron Kantoff — Co-Founder and Managing Partner at Scion Life Sciences.Aaron helped build the therapeutics group at Apple Tree Partners from scratch, co-founding 11 companies along the way. After leaving Apple tree, Aaron co-founded RayzeBio, which was acquired by BMS for $4.1B.Now at Scion, he's continuing to back and build bold biotech companies with long-term potential — and a fresh approach to VC.We talk about the companies he’s built, what he’s learned from them, and why Scion is doubling down on science-first biotech in today’s market.Enjoy and stay tuned.

Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry.I’m joined by Rick Winningham, Chairman and CEO of Theravance Biopharma.Rick has led Theravance since its spin-out from Innoviva in 2014, after serving as CEO of Innoviva and holding senior leadership roles at Bristol Myers Squibb. He’s also been a driving force in industry advocacy, chairing the California Life Sciences Association and serving on the boards of Jazz Pharmaceuticals, Rivus, and BIO.At Theravance, he’s steering strategy, innovation, and execution in a challenging market — drawing on decades of experience to navigate cycles, build strong teams, and keep advancing transformative medicines.Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.I’m joined by Gerardo Ubaghs, CFO of Frontier Medicines. Gerardo has had one of the most unique career journeys you’ll hear — from being a professional violinist, to working in investment banking, and then stepping into biotech where he’s helped build and finance some of the most innovative companies out there. At Frontier, he’s driving strategy and finance for their mission to unlock previously undruggable targets using chemoproteomics and AI to develop precision medicines.Enjoy and stay tuned.

Welcome to another episode of The Bio Hub. We were thrilled to welcome Jaideep Dudani, Founding CEO of Ouro Medicines and Portfolio Principal at Monograph Capital. Jaideep holds a PhD from MIT and a BS in Bioengineering from UCLA. Jaideep began his career at Vida Ventures and played key R&D, strategy, and business development roles at Relay Therapeutics. Jaideep later helped launch Human Immunology Biosciences (HI Bio), leading portfolio development and strategic initiatives prior to its acquisition by Biogen.In early 2025, he co founded Ouro Medicines—backed by Monograph, GSK, NEA, TPG, Norwest, and others to pull of an incredible $120M Series A, to pioneer ‘immune reset’ T cell engager therapies targeting B cell mediated autoimmune and inflammatory diseases. We’ll explore Jaideep's journey from bioengineering research to biotech entrepreneurship, as well as the promising data from Ouro Medicines as well as Jaideep’s experience with building biotechs out from the ground up.

So welcome back to another episode of the Bio Hub, we were delighted to welcome Alec Ford (CEO of Karius) and Stacy Solorio (Chief people Officer at Karius). Alec is a veteran of the genomics and biotech industries with over 30 years of leadership experience. Alec is leading the charge in transforming infectious disease diagnostics through Karius’s groundbreaking liquid biopsy test, which uses microbial cell-free DNA and AI to detect over 1,000 pathogens from a single blood draw. Before joining Karius, Alec served as COO at Myriad Genetics, where he scaled diagnostics across oncology, women’s health, and prenatal care, and held senior roles at Pfizer, Novartis, Sanofi, and Nektar. His leadership is deeply informed by personal experience—his family’s encounter with severe infections underscored the critical need for faster, more precise diagnostics.Stacy Solorio is the Chief People officer at Karius. Stacy is a strategic people leader with deep expertise in building culture and scaling teams within fast-growing biotech organizations. She’s also the founder of Biocom’s HR Biotech Group and Executive HR Education program, and serves on the board of the Biocom California Institute. At Karius, she’s helping align talent initiatives with the company’s mission to bring cutting-edge diagnostics into clinical practice.

We were delighted to welcome Dr. Dan Williams, CEO and co-founder of SynaptixBio, a pioneering biotech company on a mission to develop life-changing treatments for children affected by devastating brain disorders, onto the bio hub. With over two decades of experience in the biotech and pharmaceutical industries, Dan has led teams from the lab bench to global clinical programs, and now he’s tackling one of the rarest and most challenging neurological diseases: TUBB4A-related leukodystrophies, including the severe H-ABC form.Under Dan’s leadership, SynaptixBio is leveraging cutting-edge antisense oligonucleotide (ASO) technology to silence disease-causing genes and bring hope to families with no existing treatment options. In just a few years, his team has secured orphan drug designations, raised significant funding, and is driving toward clinical trials with an urgency that reflects the needs of the patients they serve.We’ll talk to Dan about his journey from scientist to biotech CEO, the science behind SynaptixBio’s approach, and what it takes to bring a rare disease therapy from concept to clinic.

We were delighted to welcome Adam Thomas, Chief People & Experience Officer at MOMA Therapeutics onto the Bio Hub, where he brings over two decades of strategic HR leadership across the biotech, pharmaceutical, and consumer industries. Since joining MOMA in 2024, Adam has led the company’s people and culture strategy during its pivotal transition into a clinical-stage organization, focusing on creating a world-class employee experience that integrates physical, digital, and cultural environments. Prior to MOMA, he served as Chief People Officer and Corporate Secretary at Synlogic, Inc., where he guided HR and talent strategy through the company’s growth from pre-clinical to Phase III development. He also held senior HR leadership roles at Shire Pharmaceuticals, where he oversaw HR for Research & Development during a major expansion, and at SC Johnson, leading HR for Research, Development & Engineering with an emphasis on talent development and organizational effectiveness. Earlier in his career, Adam spent over a decade at Pfizer in a variety of HR leadership roles and held advisory and research roles at Gartner (formerly CEB) and Brann Worldwide. He holds an LL.B. in Law from the University of Edinburgh, an M.A. in Human Resource Management from the University of the West of England, and an M.B.A. from Boston University

Lisa DiPaolo is the Executive Vice President and Chief Human Resources Officer at Karyopharm Therapeutics, where she brings over two decades of HR leadership in the pharmaceutical and biotech industries. Since joining Karyopharm in September 2022, she has led the company’s People & Culture strategy through a critical period of growth and transformation. Before this, Lisa served as SVP of HR at Ipsen, overseeing North America as well as global R&D and Business Development, where she drove significant organizational and cultural shifts. She also spent eight years at Biogen in a series of senior roles, including leadership of global therapeutic operations, executive search, and medical affairs HR. Her earlier career included HR leadership roles at Smiths Medical and nearly a decade at Novartis, managing both U.S. and global teams. Lisa holds a B.A. from Montclair State University and an M.S. in Human Resource Management from Rutgers University. Known for her focus on authentic leadership, culture-driven transformation, and scalable HR systems, she is passionate about creating resilient, people-centric organizations that align business goals with strong employee experience.

Dr. Aaron Royston, M.D., M.B.A., is a Managing Partner at venBio, a life sciences venture capital firm, where he brings over 15 years of experience in biotechnology investing, company formation, and clinical research. His leadership has contributed to the launch and growth of several successful biotech companies, including Apellis Pharmaceuticals, Ventyx Biosciences, Akero Therapeutics, Harmony Biosciences, and RayzeBio, collectively achieving multiple FDA drug approvals. Before joining venBio, Dr. Royston was part of the investment team at Vivo Capital and worked at Bain & Company, advising biotechnology firms on strategic and operational matters. He began his career coordinating clinical research at Mount Sinai Medical Center, with his work published in various medical journals. Dr. Royston holds a B.S. in Biological Sciences from Duke University and earned both his M.D. and M.B.A. from the University of Pennsylvania. As a student, he founded a technology company that was later acquired, earning him recognition from the White House in 2010 as a Champion of Change for his contributions to technology and innovation. In addition to his role at venBio, Dr. Royston serves on the boards of multiple biotech companies, including Candid Therapeutics, Attovia Therapeutics, 35 Pharma, and ViceBio.

Dr. Harith Rajagopalan is the Co-founder and CEO of Fractyl Health, a company he launched while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Before founding Fractyl, Dr. Rajagopalan was an academic cardiologist and physician-scientist. He earned his B.S. in Chemistry from Stanford University and obtained both M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, he conducted award-winning research on intestinal cancers, with findings published in leading journals such as Nature and Science. Following medical school, he completed his residency in internal medicine and fellowship in clinical cardiology at Brigham and Women’s Hospital, along with a research fellowship at the Harvard Stem Cell Institute. Under Dr. Rajagopalan's leadership, Fractyl Health has developed innovative therapies targeting metabolic diseases. Notably, the company is advancing Rejuva®, a gene therapy platform designed for long-term remission of obesity and type 2 diabetes by altering metabolic hormone function in pancreatic islet cells. Rejuva is expected to enter first-in-human studies in the first half of 2025.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.In this special follow-up episode, I’m rejoined by Marc de Garidel, CEO of Abivax, after our hugely popular conversation last year—recorded just after their record-breaking NASDAQ IPO. That episode gave us a look into Marc’s incredible career, the company’s bold vision, and how they were gearing up to become a major player in inflammatory diseases.This time, he’s joined by Sylvie Grégoire, Chair of the Abivax Board—a hugely respected industry leader with decades of global biotech and pharma experience.Together, we dive into what’s changed in the past year, how they’re navigating today’s biotech climate, and what’s next for Abivax as they continue to push forward in ulcerative colitis and beyond.Two powerhouse leaders. One big conversation. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.I’m joined by Lisa Deschamps, CEO of AviadoBio.After 25 years at Novartis, leading global launches in gene therapy, she’s now at the helm of AviadoBio—developing treatments for FTD and ALS.We talk career moves, mindset, culture, and what’s ahead.Enjoy and stay tuned.

We were delighted to be joined by Julie Person on the BioHub podcast, an accomplished human resources and organizational leader with over 20 years of experience in the biopharmaceutical industry. She currently serves as Chief Administrative Officer at Third Harmonic Bio, where she leads company operations, including human resources, communications, and organizational strategy.Julie has a strong track record of helping biotech companies scale and thrive through critical growth stages. Prior to her current role, she was Chief People Officer at Neumora Therapeutics, and held senior HR leadership positions at Sangamo Therapeutics, Audentes Therapeutics, Shire, and Baxalta. Her expertise lies in building high-performing teams, shaping company culture, and aligning talent strategies with business goals.She holds a degree from Saint Mary's College of California and completed an Executive Leadership Program at the University of Michigan Ross School of Business.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.I’m joined by Alexander Zehnder, CEO of CureVac — a company that’s been pioneering mRNA technology for 25 years.Alexander stepped into the CEO role in 2023 and has been leading CureVac through a critical transformation: securing a €1.45 billion partnership with GSK, executing a strategic pivot, and driving a major cultural shift within the organization. With a background in medicine and a career spanning Roche, Genentech, and Sanofi, he brings a unique perspective on what it takes to lead at scale while staying patient-focused.We dive into the evolution of mRNA, the story behind CureVac’s next chapter, and the mindset needed to lead through change.Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.I’m joined by Dr. Claudia Zylberberg — a pioneering force in cell and gene therapy and the founder of Akron Biotech.Claudia has spent her career shaping the future of biologics manufacturing, building Akron into a key player in the CGT ecosystem, and championing the development of global standards for advanced therapies. She’s a scientist, an entrepreneur, and an advocate for innovation, quality, and access in one of the most complex areas of biotech.From founding startups to influencing international policy, Claudia brings a wealth of experience and insight to the table — and I can’t wait to get into it.Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.On this episode of The BioHub, I’m joined by Uwe Schoenbeck, Partner at Canaan and one of the most respected names in early-stage biotech.After more than a decade leading external science and innovation at Pfizer, Uwe made the jump to venture capital, joining Canaan in 2023. With a background spanning big pharma, startups, and science itself—he’s uniquely positioned to see what’s coming next.In this episode, we talk about the shift from pharma to VC, what founders get wrong when pitching, and the traits that separate the good companies from the great ones.Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. I’m joined by Gwen Acton, CEO of Vivo Group and an expert in leadership development for scientists, engineers, and biotech professionals.Gwen has had a fascinating career—she earned a PhD from MIT, was a faculty member at Harvard, ran operations at the Whitehead Institute during the Human Genome Project, and has helped thousands of technical experts become stronger leaders.Now, she’s adding “author” to her resume with a brand-new book on leadership, and today, we’re diving into why leadership is so crucial in biotech, how it’s evolved, and what inspired her to write it.Enjoy and stay tuned

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.Today we're joined by David De Graaf, CEO of Co-Founder of Reverb TherapeuticsDavid has an incredible background, with positions at companies such as AstraZeneca, Pfizer, Apple Tree Partners & Boehringer Ingelheim as well being at the helm of multiple successful biotechs. In this episode, we dive into his journey, building out seed stage biotech's from scratch as well as the Canadian Biotech scene

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.I’m joined by Judy Chou, CEO of AltruBio—one of the mostexciting biotech companies out there, especially after closing the largest Series B in biotech over the last four years. Judy has an incredible background, having led global biotechat Bayer, held leadership roles at Pfizer, and served as research faculty at Harvard. Now, as the CEO of AltruBio, she’s driving the company’s mission to develop first-in-class immune modulators for autoimmune and inflammatorydiseases.In this episode, we dive into her journey, how AltruBio isthriving in a tough market, and what’s ahead for the company in 2024. Let’s get into it!Enjoy and stay Tuned.